Home Health Index December Update
No single theme dominated the home health and post-acute care indices in 2023. At year’s end, there were companies up big, and companies down big.
The reasons for that are hard to decipher. But there are some signs to point toward.
Amedisys Inc. (Nasdaq: AMED), for one, is up because UnitedHealth Group (NYSE: UNH) plans to take it over. Enhabit Inc. (NYSE: EHAB) is down because of staffing and Medicare Advantage (MA) headwinds, which led to its strategic review in the first place.
On the other end, Addus is down over 6% on the year. The company has had what its leaders would likely consider a successful year, but its stock price could be down simply because of a rule proposed by the Centers for Medicare & Medicaid Services (CMS) regarding mandates for caregiver wages in home- and community-based services.
The Pennant Group is up over 25%, and continues to blaze the M&A trail. Aveanna Healthcare Holdings (Nasdaq: AVAH) is down nearly 2%.
Whether they increased their stock prices in 2024 or not, all of these companies are hoping for a better year in 2024 – whether in macroeconomics, workforce, regulatory or something else.
“It was a tough operating environment for most post-acute and home health companies in 2023,” says Joe Lynch, partner and managing director at Stoneridge Partners. “These companies are battle tested, but 2024 is likely to come with a lot of the same challenges.”
Home Health Index
Enhabit should be nearing a sale sooner rather than later. Its earnings call in February should lead to further clarity on its future.
In December, its stock price dipped by 3%. Overall, the company is down 58% since it went public back in June of 2022, from a stock price of $24 to around $10 at the close of December.
Where Enhabit lands will be of great interest. After all, it’s an at-scale, independent home health and hospice provider. There aren’t many of those left.
Once UnitedHealth Group’s Optum closes on its deal for Amedisys, it will own about 10% of the home health market. That’s considering Amedisys will be under the same umbrella as LHC Group.
Another company — such as Humana Inc. (NYSE: HUM) — could try to bolster its footprint to about that size with a purchase of Enhabit. But at the same time, Humana has itself been in transaction rumors.
Amedisys has hovered around its sell price over the course of the last six months. It’s up over 13% on the year and was up over 1% in December.
Post-Acute Care Index
In November, Aveanna was one of the big winners, gaining over 50% in one month alone. In December, things cooled down. The company was down by about 1% month over month.
In December, it found its new CFO in Matt Buckhalter. Aveanna has had a lot of leadership turnover over the past year, but things finally seem to be settling.
Buckhalter was the interim CFO and was ultimately given the keys to the permanent position.
“Matt has provided strong financial leadership and continuity as we build on our recent successes to transform our business,” Aveanna CEO Jeff Shaner said in a statement. “I have great confidence in the collaborative relationship between Matt, serving as our chief financial officer, and Deborah Stewart, continuing to serve in her role as our principal accounting officer. The leadership they bring to our accounting and finance teams, and Aveanna overall, is critical as we focus on executing our key initiatives into 2024.”
All the while, Pennant continued its upward trajectory. It was up over 1% in the month and, again, up 26.78% on the year.
The company continues to execute on home health and hospice deals, which will likely be a trend in 2024 as well.
It also entered a home health joint venture with John Muir Health at the start of the year.
“We are thrilled to begin operating this joint venture,” Pennant CEO Brent Guerisoli said in a statement. “Muir Home Health will bring together the deep experience of one of the Bay Area’s premier health systems with Pennant’s deep experience in managing and supporting the delivery of life-changing home health services. This collaboration will create a unique continuum of care that will benefit Bay Area residents for many years to come.”
Quote of the Month
“Where we can bring together a continuum of services and infuse innovation, the result is a game-changer for our seniors because it simplifies the health care experience, his work is especially important given the persistent staffing challenges that are not going away anytime soon, and are more acute in rural areas, where 70% of our residents live.” -Nate Schema, President and CEO of The Evangelical Lutheran Good Samaritan Society
Read the Full Article Here: Nursing Homes’ Road From Recovery to Stability Under Threat
See It To Believe It!
The Stoneridge Partners Home Health Index (HH Index) is updated monthly and measures the performance of these two publicly traded home health companies, all listed on the NASDAQ:
*NOTE: LHC Group was officially delisted from the Nasdaq when UnitedHealth Group’s (NYSE: UNH) acquisition of it was finalized. While LHC Group is now gone from the HHI, Enhabit has been added in the past year. The numbers below are reflected as such.
- Amedisys (AMED)
- Enhabit (EHAB)
Here are the results of the stock prices for the past two years:
Company | 12/31/23 | 1 mos change | YTD change | 12/31/22 | 12/31/21 |
Amedisys | 95.06 | +1.56 | +13.79% | 83.54 | 161.88 |
Enhabit | 10.35 | -3.00% | -21.35% | – | – |
HH Index* | 52.71 | +1.11% | -57.02% | 122.62 | 149.56 |
S&P | 4769.83 | +4.24% | +23.01% | 3877.67 | 4766.18 |
Addus | 92.85 | +6.09% | -6.67% | 99.49 | 93.51 |
Although we track the performance of Addus, they are not included in our HH Index because very little of their revenue comes from Medicare.
Enterprise Value (EV)
EV (in M) | 2023 | 2022 | 2021 |
Amedisys | 3510 | 2760 | 5240 |
Enhabit | 1110 | – | – |
HH Index Total | 4620 | 8660 | 9460 |
Addus | 1640 | 1650 | 1460 |
Enterprise Value (EV), aka Selling Price, as Percent of Revenue
Company | 2023 | 2022 | 2021 |
Amedisys | 158% | 149% | 257% |
Enhabit | 105% | – | – |
HH Index Average* | 132% | 203% | 236% |
Addus | 160% | 189% | 188% |
The Stoneridge Partners Post-Acute Care Index is updated monthly and measures the performance of these six publicly traded post-acute care companies, all listed on the NASDAQ:
- Aveanna (AVAH)
- Amedisys (AMED)
- Addus (ADUS)
- The Pennant Group, Inc. (PNTG)
- Enhabit (EHAB)
- Brookdale Senior Living Inc. (BKD)
Here are the results of the Post-Acute stock prices for the past two years:
Company | 12/31/23 | 1 mos change | YTD change | 12/31/22 | 12/31/21 |
---|---|---|---|---|---|
Amedisys | 95.06 | +1.56% | +13.79% | 83.54 | 161.88 |
Addus | 92.85 | +6.09% | -6.67% | 99.49 | 93.51 |
Pennant | 13.92 | +1.44% | +26.78% | 10.98 | 23.08 |
Brookdale | 5.82 | +8.93% | +113.19% | 2.73 | 5.16 |
Enhabit | 10.35 | -3.00% | -21.35% | 13.16 | – |
Aveanna | 2.68 | -1.87% | +243.59% | 0.78 | – |
Enterprise Value (EV)
EV (in M) | 2023 | 2022 | 2021 |
---|---|---|---|
Amedisys | 3510 | 2760 | 5240 |
Addus | 1640 | 1650 | 1460 |
Pennant | 733 | 641 | 924 |
Brookdale | 556 | 526 | 569 |
Enhabit | 1110 | – | – |
Aveanna | 1810 | – | – |
Enterprise Value (EV), aka Selling Price, as Percent of Revenue
Company | 2023 | 2022 | 2021 |
---|---|---|---|
Amedisys | 158% | 149% | 257% |
Addus | 160% | 189% | 188% |
Pennant | 140% | 139% | 212% |
Brookdale | 189% | 195% | 198% |
Enhabit | 105% | – | – |
Aveanna | 97% | – | – |
This graph displays 24 months of Post-Acute Care Index performance.
The above calculations are based on selling price being defined as Enterprise Value (EV), with data provided by Capital IQ. Enterprise value is defined as market cap plus debt, minority interest and preferred shares, minus total cash and cash equivalents. EBITDA is calculated using methodology which may differ from that used by a company for its reporting. (Home Health Index December 2023 | Stoneridge Partners)
Recent Transactions From Around The Country
-
Residential Hospice has acquired Illinois-based Safe Haven Hospice from the senior living provider Christian Horizons.
-
Fortis Health Acquires Physiocare Home Health and Hospice.
-
Uwill Acquires Christie Campus Health, Expands College Mental Health Services.
-
New Day Healthcare Acquires Compassion Hospice.
SOLD by Stoneridge!!!
- Stoneridge Partners is proud to announce the successful sale of an Intellectual and Developmental Disabilities Agency in Minnesota.
- Stoneridge Partners is proud to announce the successful sale of a Home Health Care Agency in Missouri.
- Stoneridge Partners is proud to announce the successful sale of a Home Health Care Agency in Pennsylvania.
View Stoneridge closed transactions on our website
Exclusively Listed For Sale By Stoneridge Partners.
Do you know of any acquisitions that have taken place? We are interested in your comments. Contact us at Stoneridge Partners.
Do you know of any acquisitions that have taken place? We are interested in your comments. Contact us at Stoneridge Partners.
$9M+ in revenue with $1.8M in EBITDA. 4 locations with 30 years in the community. Strong tenured staff conducting over 27,000 appointments annually. CON state...
Hospice. 100+ ADC. Accredited. No CAP or regulatory issues.
$5M in revenue. Located in Northern/Richmond VA. Health system-owned Medicare home health and hospice. Growing organization.
Non-medical Home Care agency. $2M+ in revenue. Medicaid. Profitable.
Non-medical Home Care agency. $3M+ in revenue. Multiple offices.
Hospice. 100+ ADC. Multi-location. No CAP or regulatory issues.
Large multi-discipline pediatric therapy practice. $5+M in revenue. Multiple offices with a wide geographical footprint. Full compliment of management and staff in place.
Medicare-certified home health. Opportunity to establish home health presence in Texas. Minimal census.
$14.9M in revenue with $3M of EBITDA. Second largest residential treatment provider for SUD in KY. Over 350 beds for residential, PHP, IOP, and OP...
$4.1M+ in revenue with $1.7M+ of EBITDA. Community-based outreach program offering mental health services to primarily children and adolescents. High barrier to entry; accreditation required....
$4.5+M Houston-based Medicaid home care company. Established 13 years ago. Excellent HHSC contracts are in place, resulting in an impressive bottom line. Fully staffed.
Non-medical home care franchise. $2M in revenue. 60% private pay. 20% EBITDA. Houston market.
Medicare/Medicaid-certified home health agency. $1.4M in revenue. District 9. Profitable. Accredited.
Behavioral health, therapy, and educational services business. $1.8M in revenue with over $600,000 EBITDA. Services include ABA, early intervention services to children aged 0-21, and...
Home Care Agency. $12M in revenue. 97% Medicaid. Highly profitable agency with strong growth trajectory.
$3.2 million in revenue. JCAHO accredited Home Health company. Showing remarkable growth trends and is very profitable.
Home Health & Hospice with $4.5M in revenue. Medicare/Medicaid certified. Excellent growth potential in large service area.
Hospice with $2.4M+ in revenue. Medicare/Medicaid certified. Full complement of staff in place.
Home care agency. $30M+ in revenue. 95% Medicaid. Platform opportunity.
$3M pediatric agency in Chicago. Long-term management in place.
Medicaid-certified home care. Minimal census. Opportunity to establish home care presence in Texas.
Hospice business. Low census. The license covers all of Clark County (Las Vegas and Henderson)
Non-medical home care franchisee. $9.6+M in revenue. 50% Medicaid/30% Private Pay/ 14% VA/ 6% Misc. Experienced management team to stay post-transition.
$2M revenue home care agency. 100% private pay. Primarily non-medical. Skilled designation, not Medicare-certified. W-2 caregivers. Region 8. Accredited.
Profitable private-duty home health agency in Northern Virginia. $1.5M in revenue. 20+ years in the community.
Profitable home care franchise with consistent sales growth. Revenue of $1.3M. Great reputation within the community.
$40M+ home care agency with 20+% AEBITDA. Primarily private-duty, non-medical (90%). Medicaid waiver programs. 40% family caregivers. Multiple locations.
Home Care / Pennsylvania / Popular
Medicare-certified home health agency. Houston/Kingwood area. Approximately $600k in revenue. Accredited.
Medicare-certified home health agency. District 7. Census of approximately 30 patients. Accredited.
Medicare home health agency. Health system relationship. Rare KY CON opportunity, multiple counties
Home Health / Kentucky / Popular
Home health with $8M in revenue. Medicare/Medicaid-certified. 90+% traditional Medicare/episodic. Services central Texas and licensed for entire state. Strong management team in place.
Home Health / Texas / Popular
Medicare-certified home health agency. Houston-area. Minimal census.
Home Health / Texas / Popular
Medicare-certified home health agency. District 3. Approximately $700k in revenue. Accredited.
Medicare-certified home health agency. District 5. Minimal census. Accredited.
Home Health Index December 2023 | Stoneridge Partners
From Joe Lynch, Publisher of “Home Health Index.” Joe can be reached at [email protected] or (239) 561-0826, and toll-free at 800-218-3944. Previous editions of this monthly newsletter can be searched for at the bottom of the home page of the Home Health Index.